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ABSTRACT  
Background: Assessing Quality of life of Migraine patients is important so as to manage the Headache and to implement some interventional  
programs in order to improve the quality of life of these patients. The study aims to find out the impact of Migraine on qual ity of life of Migraine 
patients. 
Material and method: This was a Prospective, Observational and questionnaire-based study, conducted from March to August 2019 for a 
period of 6 months, after approval from Institutional Ethics Committee. Data was analysed using Statistical Package for Social Sciences (SPSS) 
version 25. The quality of life in Migraine (HIT-6) was used for collecting data on Quality of Life. 
Results: Among 100 patients 81 were Females accounting for 81% of total study population and 19 were Males accounting for 19% of total 
study population. Majority of the patients were in the age range of 33-39 (30%). These were the Social History of the Patients among which 
16(16%) patients were smokers, 20(20%) consumed alcohol, 21(21%) smoke and consumed alcohol and 43 (43%) did not smoke nor 
consumed alcohol. 44 patients were from nuclear family and 56 were from joint family. The age of onset of migraine was more i n the age of 21-
30 that is (33%) as compared to other age groups. In this study the patients were to drug therapy planned to be given to them- amitriptyline 
and propranolol. The mean value for quality of life (QOL) before amitriptyline treatment was found to be 78.32 and the mean value for quality 
of life (QOL) before propranolol treatment was found to be 73.60 which comes under the score of ≥60 in accordance of HIT-6 that indicates 
severe impact on migraine patients. The HIT score after amitriptyline was found to be 46.5 and HIT score of propranolol was recorded to be 
60.5. The score with amitriptyline falls under scoring 49 or less which indicates that the headache have little or no impact on QOL. And score of 
60.5 with propranolol indicates that still headache have severe impact on QOL of the patient.  
Conclusion: Migraine patients had poor Quality of Life, which affected their pain and role functioning. It is very important to improve their 
Quality of life so that they can enjoy their day to day life. 
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Migraine is a chronic neurologic disorder characterized by 
repeated pulsating headaches that are moderate to severe.[1] 
Normally, the headaches affect one half of the head, are 
pulsating in nature, and last from 2 to 72 hours.[1] Related 
symptoms may include nausea, vomiting, and sensitivity to 
light, sound, or smell.[2] The pain is generally made worse by 
physical activity.[3] Up to one-third of an individuals have an 
aura: typically a short period of visual disturbance that 
signals that the headache will soon occur. [3] Occasionally, an 
aura can occur with little or no headache following it.[4] 
Migraines are supposed to be due to the combination of 
environmental and genetic factors.[5] About two-thirds of 
cases run in families.[6] Changing hormone levels may also 
play a role, as migraines affect slightly less girls than boys 
before puberty and two to three times more women than 
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men.[7][8] The risk of migraines usually decreases during 
pregnancy.[7] The underlying mechanisms are not fully 
known.[9] They are, however, believed to involve the nerves 
and blood vessels of the brain.[6] 
Worldwide, migraines affect nearly 15% or approximately 
one billion people.[10] It is more common in women at 19% 
than men at 11%.[10] These figures vary substantially with 
age: migraines most commonly start between 15 and 24 
years of age and occur most frequently in those 35 to 45 
years of age.[6] During perimenopause symptoms often get 
worse before decreasing in severity.[11] While symptoms 
resolve in about two thirds of the elderly, in between 3 and 
10% they persist.[12] 
The underlying causes of migraines are unknown.[13] 
However, they are believed to be related to a mix of 
environmental and genetic factors.[5] Studies of twins shows 
a 34% to 51% genetic influence of possibility to develop 
migraine headaches.[5] This genetic relationship is stronger 
for migraines with aura than for migraines without aura.[14] 
A number of specific variants of genes increase the risk by a 
small to moderate amount.[15] 
Quality of Life: 
Quality of life has been defined as the ability of an individual 
to play a role in society and to enjoy fully their role as a 
citizen, with an independent social status [16]. It refers to an 
individual’s assessment of their general well-being and 
position in life as perceived within the context of their 
culture, value systems, goals, and concerns. HRQOL is a 
subset of overall quality of life representing the overall effect 
of illness and its therapy on a patient. It encompasses an 
individual’s health state, functional status (both physically 
and mentally), as well as the individual’s overall well-being 
[17]. A generally applicable definition of HRQOL is one that 
includes both subjective perception on one’s life situation 
and objective registrable health factors. Measurements of 
HRQOL, a multidimensional concept, and disability have 
become increasingly accepted as tools for assessing the 
functional impact of a disease and evaluation of the burden 
of headache. The available data indicate that the individual’s 
personality, the headache attacks, or their treatment or both, 
can influence the patient’s health-related quality of life 
(HRQOL). [18,19]. 
Many instruments have been used to analyze the difference 
in the quality of life associated with headache diagnoses, 
recent research has led to the identification of specific 
dimensions of QOL and their incorporation into both valid 
and reliable instruments. 
MATERIALS AND METHOD: 
The study was conducted in Tertiary Care Hospital, 
Dehradun. The patients attending the outpatient facilities of 
the department of neurology with clinical diagnosis of 
migraine were included in the study. This was a prospective, 
observational and questionnaire-based study, conducted 
from March to August 2019 for a period of 6 months, total 
100 migraine patients were enrolled in the study that 
satisfies the inclusion and exclusion criteria. Inclusion 
criteria were male and female patients who were willing to 
participate of age 18-60 years, and with the diagnosis of 
migraine. Exclusion criteria were patients with pregnancy 
and lactation period, and patient below 18 years and above 
60 not willing to participate. An interview was performed 
with the use of a HIT-6 questionnaire to assess the quality of 
life. Informed consent form was obtained from each patient. 
In this study HIT-6 Questionnaire was used in which, items 
of the HIT-6 cover several HRQOL domains: pain, social 
functioning, role functioning, vitality, cognitive functioning, 
and psychological distress. 
Statistical analysis 
Data was analysed using Statistical Package for Social 
Sciences (SPSS) version 25. Mean and standard deviation for 
each of the QOL score and comparison of Amitriptyline and 
Propranolol were calculated. Paired sample t-test was used 
to compare the means between group. Pearson correlation 
was used to calculate the correlation. The results were 
tabulated and graphically represented using Microsoft Excel 
for Windows 2010. 
RESULTS 
A study was conducted on 100 patients, from which 50 were 
prescribed with Amitriptyline and 50 with Propranolol to 
gather the information about their quality of life. 
Demographic Profile of the Patients 
The demographic profile of the patients includes gender wise 
distribution of patients, age-wise distribution of patients and 
socio-economic parameter of the patients involved in the 
study. 
1. Gender Wise Distribution of Patients 
Among 100 patients 81 were Females accounting for 81% of 
total study population and 19 were Males accounting for 
19% of total study population. 
 
Fig 1: Gender wise distribution of patients who were 
taking Amitriptyline and Propranolol. 
2. Age wise distribution of patients: 
Maximum Drugs were taken by the patients of age group 
between 33-39 yrs. 
 
Fig 2: Age wise distribution of patients who were taking 























Kothiyal et el                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(5-s):40-43 
ISSN: 2250-1177                                                                                  [42]                                                                                 CODEN (USA): JDDTAO 
3.  Social History: 
In total number of 100 patients, 16(16%) patients were 
smokers, 20(20%) consumed alcohol, 21(21%) smoke and 
consumed alcohol and 43 (43%) did neither smoke nor 
consumed alcohol. 
 
Fig 3: Distribution of subject on the basis of social 
history 
4.  Type of Family: 
It was observed that in total 100 patients, 44 patients were 
from nuclear family and 56 were from joint family. 
 
Fig 4: Distribution of subject on the basis of family type 
5. Age at the onset of migraine: 
From 100 patients, the age of onset was more from the age of 
21-30 that is (33%) as compared to other age groups. 
 
Fig 5: Distribution of subject on the basis of age of onset 
of migraine 
 
6. Assessment of Quality of Life: 
Among 100 patients 50 were prescribed with Amitriptyline 
and 50 with Propranolol. Quality of life was assessed before 
the treatment was initiated, by using the HIT-6 
Questionnaire. 
 
Fig 6: Quality of life in migraineurs 
7. Assessment of Quality of Life after taking 
Amitriptyline and Propranolol 
          
Fig 7: Quality of life in migraineurs after Amitriptyline 
and Propranolol Treatment 
DISCUSSION 
In present study, about 100 patients were selected on the 
basis of exclusion and inclusion criteria. Out of 100 patients 
female patients were more affected than male patients. 
About 81 (81%) were female and while male were 19 (19%). 
According to Kartavya Sharma et al,[20] females had 
significantly higher impairment in physical HRQoL scales 
compared to males even after adjusting for headache 
frequency, severity, disability, and psychiatric illness. 
In the present study, the patients of age group 33-39 years 
were more commonly affected. Among 100 patients, lower 
incidence rate of disease affect had been shown in the age 
group 41-60 years, which was found to be in 27 (27%) 
patients. Higher incidence rate of disease affect had been 
shown in the age group of 18-40 years, which was found to 
be in 73 (73%) patients. According to Kuldeep Moras et al,[21] 
in the study of 100 patient, the incidence of migraine were 
found more common in the age group between 30-40 years. 
In the present study the Quality of life was found to be poor 
in migraine patients and similar findings were noted 
according to Munvar Miya Shaik et al,[22] in this study 
measurements of QOL and disabilities have emerged as 
important complementary approaches for the evaluation of 
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QOL and health was significantly lesser among migraine 
patients. 
According to the present study, HIT-6 shows beneficial effect 
in assessing the quality of life in migraine patients. In this 
study the mean value before amitriptyline treatment was 
found to be 78.32 and the mean value before propranolol 
treatment was found to be 73.60 which comes under the 
score of ≥60 in accordance of HIT-6 which indicates severe 
impact in migraine patients. Patients might be experiencing 
disabling pain and other symptoms that are more severe 
than those of other headache sufferers. 
After proper treatment was given to the patients with 
amitriptyline and propranolol, again the QOL was being 
measured using the same HIT questionnaire. The HIT score 
after amitriptyline was found to be 46.5 and HIT score of 
propranolol was recorded to be 60.5. The score with 
amitriptyline falls under scoring 49 or less which indicates 
that the headache have little or no impact on QOL. And score 
of 60.5 with propranolol indicates that still headache have 
severe impact on QOL of the patient. 
Thus, it was noted that after treatment with amitriptyline 
and propranolol. Amitriptyline has much better effect in 
improving the QOL of the patients that treatment with 
propranolol. 
CONCLUSION 
Severe migraine attacks have a negative effect on functioning 
and quality of life including pain, and role functioning of 
daily life. Improvement in quality of life is a vital part of this 
process, as it helps all involved healthcare providers deliver 
appropriate care. The evidence presented in the current 
study shows that the patients suffering from migraine had 
poor quality of life. 
Migraine prophylaxis with amitriptyline, decreased the 
frequency of symptoms and also reduction in days of 
migraine attack thus improving the quality of life in 
migraineurs. Rather in Propranolol somehow decrease in 
frequency of symptoms and there is no reduction in days of 
migraine attack thus have severe impact on quality of life. 
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